Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower
Odyssey Therapeutics (ODTX) debuted on Nasdaq at $20, raising $279M via an upsized offering. Shares initially climbed 13% but later fell 10% to $16. The company also raised $25M in a private placement, totaling $304M. Proceeds will fund drug development, including OD-001 for ulcerative colitis and Crohn's disease. The company reported net losses of $148.6M in 2025 and $129.3M in 2024, with $175.7M in cash as of March 2026.
How this was made
The 30-second read
Why it matters
The $304M raise provides runway for pipeline advancement but the volatile debut highlights market uncertainty.
Market read
First‑day IPO performance and sizable capital raise make this a notable event for biotech investors.
What to watch
Potential dilution from underwriter option and upcoming clinical trial results could affect long‑term valuation.
Background
Odyssey Therapeutics is a Boston‑based clinical‑stage biotech focusing on ulcerative colitis and Crohn's disease treatments.
Ticker impact
Odyssey Therapeutics raised $304M in its Nasdaq IPO and private placement, debuting at $20 and later trading at $16.
Potential short-term bounce if demand holds; downside risk if sell‑off continues.
First‑day pricing and sizable proceeds provide liquidity and visibility; market reaction will set early support levels.
Market effects
Adds to biotech IPO pipeline, may influence investor appetite for clinical‑stage companies.
Boosts Nasdaq biotech listings momentum in the US market.
Limited to US biotech sector; no broader macro effect.
Counterpoint
The rapid post‑IPO decline suggests overvaluation; short positions could profit if momentum fades.
Key entities
- CompanyOdyssey Therapeutics Inc.
Clinical‑stage biotech launching on Nasdaq.
- InvestorTPG Life Sciences Innovations
Affiliate that participated in the private placement.
